Recombinant Human CEP19 Protein, N-His

Introduction

Recombinant Human CEP19 Protein (rCEP19) is a novel protein that has gained attention in the scientific community due to its potential role in cancer biology. This protein is a product of genetic engineering, where it is produced in large quantities using recombinant DNA technology. In this article, we will explore the structure, activity, and potential applications of rCEP19.

Structure of rCEP19

rCEP19 is a 19 kDa protein that is composed of 175 amino acids. It belongs to the family of centrosomal proteins, which are essential for the proper functioning of the centrosome, a cellular organelle involved in cell division. The structure of rCEP19 consists of a central coiled-coil domain, flanked by two globular domains on either side. This unique structure is crucial for its function and interactions with other proteins.

Activity of rCEP19

The primary function of rCEP19 is to regulate the centrosome cycle, which is essential for cell division. It has been shown to localize to the centrosome during the G1 phase of the cell cycle and then dissociate during mitosis. This localization and dissociation are crucial for the proper duplication of the centrosome and subsequent cell division. Additionally, rCEP19 has been found to interact with other centrosomal proteins, such as CEP350 and CEP170, further highlighting its role in centrosome function.

Moreover, rCEP19 has been shown to be involved in microtubule nucleation, a process that is essential for the formation of the mitotic spindle during cell division. This further emphasizes the importance of rCEP19 in the proper functioning of the centrosome and cell division.

Applications of rCEP19

The potential applications of rCEP19 are vast, especially in the field of cancer biology. Studies have shown that rCEP19 is overexpressed in various cancer types, including breast, lung, and prostate cancer. This overexpression has been linked to increased cell proliferation and tumor growth, making rCEP19 a potential target for cancer therapy.

Furthermore, rCEP19 has been found to be a prognostic marker in certain cancers. In breast cancer, high levels of rCEP19 have been associated with poor patient outcomes, suggesting its potential use as a biomarker for disease progression and treatment response.

In addition, rCEP19 has been identified as a potential antigen for cancer immunotherapy. Antigens are substances that can elicit an immune response, and rCEP19 has been shown to induce an immune response in cancer patients. This makes it a promising candidate for the development of cancer vaccines or targeted immunotherapies.

Conclusion

In summary, rCEP19 is an important protein involved in the regulation of the centrosome cycle and microtubule nucleation. Its unique structure and interactions with other centrosomal proteins make it a crucial player in cell division. The overexpression of rCEP19 in various cancers and its potential as a prognostic marker and antigen for cancer immunotherapy highlight its significance in cancer biology. Further research on rCEP19 could lead to the development of novel cancer treatments and improved patient outcomes.